NS3 epitope-decorated nanoparticles produced in bacteria trigger potent T cell immunity against hepatitis C virus

Abstract

The highly conserved human leukocyte antigen-A2 (HLA-A2)-restricted epitope NS3-1073 represents a promising candidate for a therapeutic vaccine against hepatitis C virus (HCV). In this study, we engineered a set of fusion proteins based on the artificial self-assembling peptide (SAP), which were expressed in Escherichia coli and spontaneously self-assembled into nanosized particles displaying HCV epitopes, including NS3-1073. To enhance immunogenicity, we incorporated the T helper epitope PADRE into the construct. Alpha-helical linkers were introduced between SAP and the epitopes to facilitate proper protein folding. Notably, a helical linker with a high supercoiling propensity enabled soluble expression of the fusion protein containing both the NS3-1073 and PADRE epitopes, allowing purification of the in vivo-formed nanoparticles by metal affinity chromatography. Human dendritic cells derived from peripheral blood monocytes showed robust activation in response to the fusion proteins and preferentially stimulated T lymphocytes toward a Th1-biased immune response. In mice, immunization with nanoparticles carrying NS3-1073 induced splenocyte proliferation in response to in vitro stimulation with a mixture of NS3 peptides. These results demonstrate that recombinant nanoparticle-based carriers presenting the NS3-1073 epitope can be produced in bacterial systems and hold strong potential as a foundation for a therapeutic HCV vaccine.

Keywords

hepatitis C virus / NS3 epitope / nanoparticle / self-assembling peptide / vaccine

Funding

This study was partly supported by the Russian Science Foundation (Grant No. 24-25-20087 to V.K.)

Acknowledgments

We thank the donors for participating in this study.

References

[1] Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer[J]. Biol Chem, 2017, 398(8): 817-837. doi: 10.1515/hsz-2017-0118

[2] Holz L, Rehermann B. T cell responses in hepatitis C virus infection: Historical overview and goals for future research[J]. Antivir Res, 2015, 114: 96-105. doi: 10.1016/j.antiviral.2014.11.009

[3] Spengler U. Direct antiviral agents (DAAs)—a new age in the treatment of hepatitis C virus infection[J]. Pharmacol Ther, 2018, 183: 118-126. doi: 10.1016/j.pharmthera.2017.10.009

[4] Masavuli MG, Wijesundara DK, Torresi J, et al. Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C[J]. Front Microbiol, 2017, 8: 2413. doi: 10.3389/fmicb.2017.02413

[5] Raman S, Machaidze G, Lustig A, et al. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles[J]. Nanomedicine, 2006, 2(2): 95-102. doi: 10.1016/j.nano.2006.04.007

[6] Babapoor S, Neef T, Mittelholzer C, et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection[J]. Influenza Res Treat, 2011, 2011: 126794. doi: 10.1155/2011/126794

[7] Herring BL, Tsui R, Peddada L, et al. Wide range of quasispecies diversity during primary hepatitis C virus infection[J]. J Virol, 2005, 79(7): 4340-4346. doi: 10.1128/JVI.79.7.4340-4346.2005

[8] Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution[J]. J Virol, 1992, 66(5): 3225-3229. doi: 10.1128/jvi.66.5.3225-3229.1992

[9] Adugna A. Therapeutic strategies and promising vaccine for hepatitis C virus infection[J]. Immun Inflamm Dis, 2023, 11(8): e977. doi: 10.1002/iid3.977

[10] Lechner F, Wong DKH, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus[J]. J Exp Med, 2000, 191(9): 1499-1512. doi: 10.1084/jem.191.9.1499

[11] Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8⁺ T cells are required for protection from persistent hepatitis C virus infection[J]. J Exp Med, 2003, 197(12): 1645-1655. doi: 10.1084/jem.20030239

[12] Thimme R, Oldach D, Chang K, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection[J]. J Exp Med, 2001, 194(10): 1395-1406. doi: 10.1084/jem.194.10.1395

[13] Wedemeyer H, He X, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8⁺ T cells in chronic hepatitis C virus infection[J]. J Immunol, 2002, 169(6): 3447-3458. doi: 10.4049/jimmunol.169.6.3447

[14] Boettler T, Spangenberg HC, Neumann-Haefelin C, et al. T cells with a CD4⁺CD25⁺ regulatory phenotype suppress in vitro proliferation of virus-specific CD8⁺ T cells during chronic hepatitis C virus infection[J]. J Virol, 2005, 79(12): 7860-7867. doi: 10.1128/JVI.79.12.7860-7867.2005

[15] Spangenberg HC, Viazov S, Kersting N, et al. Intrahepatic CD8⁺ T-cell failure during chronic hepatitis C virus infection[J]. Hepatology, 2005, 42(4): 828-837. doi: 10.1002/hep.20856

[16] Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection[J]. Gastroenterology, 2004, 127(3): 924-936. doi: 10.1053/j.gastro.2004.06.015

[17] Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C[J]. Nat Med, 2000, 6(5): 578-582. doi: 10.1038/75063

[18] Ward S, Lauer G, Isba R, et al. Cellular immune responses against hepatitis C virus: The evidence base 2002[J]. Clin Exp Immunol, 2002, 128(2): 195-203. doi: 10.1046/j.1365-2249.2002.01840.x

[19] Lauer GM, Lucas M, Timm J, et al. Full-breadth analysis of CD8⁺ T-cell responses in acute hepatitis C virus infection and early therapy[J]. J Virol, 2005, 79(20): 12979-12988. doi: 10.1128/JVI.79.20.12979-12988.2005

[20] Manns MP, Berg T, Wedemeyer H, et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients[J]. Hepatology, 2004, 40(S1): 251A. doi: 10.1053/j.gastro.2008.02.058

[21] Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects[J]. Vaccine, 2006, 24(20): 4343-4353. doi: 10.1016/j.vaccine.2006.03.009

[22] Schlaphoff V, Klade CS, Jilma B, et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients[J]. Vaccine, 2007, 25(37-38): 6793-6806. doi: 10.1016/j.vaccine.2007.06.026

[23] Hart DNJ. Dendritic cells: Unique leukocyte populations which control the primary immune response[J]. Blood, 1997, 90(9): 3245-3287. doi: 10.1182/blood.V90.9.3245

[24] Gluckman JC, Canque B, Rosenzwajg M. Dendritic cells: A complex simplicity[J]. Transplantation, 2002, 73(S1): S3-S6. doi: 10.1097/00007890-200201151-00004

[25] Gowans EJ, Roberts S, Jones K, et al. A phase Ⅰ clinical trial of dendritic cell immunotherapy in HCV-infected individuals[J]. J Hepatol, 2010, 53(4): 599-607. doi: 10.1016/j.jhep.2010.05.007

[26] Kuzushita N, Gregory SH, Monti NA, et al. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens[J]. Gastroenterology, 2006, 130(2): 453-464. doi: 10.1053/j.gastro.2005.10.048

[27] Alexander J, del Guercio MF, Maewal A, et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses[J]. J Immunol, 2000, 164(3): 1625-1633. doi: 10.4049/jimmunol.164.3.1625

[28] Huang XJ, Lü X, Lei YF, et al. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice[J]. J Virol Methods, 2013, 189(1): 47-52. doi: 10.1016/j.jviromet.2013.01.003

[29] Arai R, Ueda H, Kitayama A, et al. Design of the linkers which effectively separate domains of a bifunctional fusion protein[J]. Protein Eng, 2001, 14(8): 529-532. doi: 10.1093/protein/14.8.529

[30] MPI Bioinformatics Toolkit. PCOILS[EB/OL]. [2025-05-01]. https://toolkit.tuebingen.mpg.de/tools/pcoils.

[31] Gomes LC, Mergulhão FJ. Effects of antibiotic concentration and nutrient medium composition on Escherichia coli biofilm formation and green fluorescent protein expression[J]. FEMS Microbiol Lett, 2017, 364(5): fnx042. doi: 10.1093/femsle/fnx042

[32] Echeverria I, Pereboev A, Silva L, et al. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells[J]. Hepatology, 2011, 54(1): 28-37. doi: 10.1002/hep.24325

[33] Jirmo AC, Koya RC, Sundarasetty BS, et al. Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8⁺ T cell responses[J]. Vaccine, 2010, 28(4): 922-933. doi: 10.1016/j.vaccine.2009.10.150

[34] Barth H, Ulsenheimer A, Pape GR, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells[J]. Blood, 2005, 105(9): 3605-3614. doi: 10.1182/blood-2004-05-1952

[35] Dolganiuc A, Szabo G. Dendritic cells in hepatitis C infection: Can they (help) win the battle?[J]. J Gastroenterol, 2011, 46(4): 432-447. doi: 10.1007/s00535-011-0377-y

[36] Tian Y, Hu D, Li Y, et al. Development of therapeutic vaccines for the treatment of diseases[J]. Mol Biomed, 2022, 3(1): 40. doi: 10.1186/s43556-022-00098-9